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ABSTRACT
Background
Transmitted HIV-1 drug resistance can compromise initial antiretroviral therapy (ART);
therefore, its detection is important for patient management. The absence of drug-associated
selection pressure in treatment-naı ¨ve persons can cause drug-resistant viruses to decline to
levels undetectable by conventional bulk sequencing (minority drug-resistant variants). We
used sensitive and simple tests to investigate evidence of transmitted drug resistance in
antiretroviral drug-naı ¨ve persons and assess the clinical implications of minority drug-resistant
variants.
Methods and Findings
We performed a cross-sectional analysis of transmitted HIV-1 drug resistance and a case-
control study of the impact of minority drug resistance on treatment response. For the cross-
sectional analysis, we examined viral RNA from newly diagnosed ART-naı ¨ve persons in the US
and Canada who had no detectable (wild type, n ¼ 205) or one or more resistance-related
mutations (n ¼ 303) by conventional sequencing. Eight validated real-time PCR-based assays
were used to test for minority drug resistance mutations (protease L90M and reverse
transcriptase M41L, K70R, K103N, Y181C, M184V, and T215F/Y) above naturally occurring
frequencies. The sensitive real-time PCR testing identified one to three minority drug resistance
mutation(s) in 34/205 (17%) newly diagnosed persons who had wild-type virus by conventional
genotyping; four (2%) individuals had mutations associated with resistance to two drug classes.
Among 30/303 (10%) samples with bulk genotype resistance mutations we found at least one
minority variant with a different drug resistance mutation. For the case-control study, we
assessed the impact of three treatment-relevant drug resistance mutations at baseline from a
separate group of 316 previously ART-naı ¨ve persons with no evidence of drug resistance on
bulk genotype testing who were placed on efavirenz-based regimens. We found that 7/95 (7%)
persons who experienced virologic failure had minority drug resistance mutations at baseline;
however, minority resistance was found in only 2/221 (0.9%) treatment successes (Fisher exact
test, p ¼ 0.0038).
Conclusions
These data suggest that a considerable proportion of transmitted HIV-1 drug resistance is
undetected by conventional genotyping and that minority mutations can have clinical
consequences. With no treatment history to help guide therapies for drug-naı ¨ve persons, the
findings suggest an important role for sensitive baseline drug resistance testing.
The Editors’ Summary of this article follows the references.
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Antiretroviral drugs have been remarkably successful in
suppressing HIV-1 infection; however, transmitted drug
resistance can reduce the efﬁcacy of ﬁrst-line regimens.
Surveys using conventional bulk sequencing in North
America and Europe, where the history of ART is extensive,
have shown that transmitted or primary HIV-1 drug
resistance is present in 8%–20% of ART-naı ¨ve persons [1–
7]. As antiretroviral drug use expands to cope with the
pandemic, adequately assessing the prevalence and trans-
mission of drug resistance mutations will be increasingly
important for optimizing treatment efﬁcacy.
Early in HIV infection, the founding virus inoculum
saturates the majority of target cells, and transmitted drug-
resistant viruses become well established in long-term
reservoirs that allow drug resistance to persist [8–10]. Because
many resistance mutations reduce replicative ﬁtness, drug-
resistant viruses not under ART drug pressure can reverse
resistance mutations to become more ﬁt [11]. Over time,
revertants outcompete the drug-resistant viruses to become
the predominant viruses in circulation; however, the rates of
mutant virus decay can vary substantially [12–14] because of
differences in ﬁtness cost. Moreover, the cost imparted by a
drug resistance mutation to viral ﬁtness can be modulated by
other resistance mutations in the virus, and thereby accel-
erate or retard decay of the mutation [15].
HIV-1 drug resistance mutations are conventionally de-
tected by bulk sequence analysis of the virus sample. Bulk
genotyping may detect certain mutations in clinical samples
at frequencies as low as 10%; however, the detection
limitation does not allow for reliable identiﬁcation of
variants that constitute less than 20%–30% of the virus
population in a sample [16]. This detection limitation is a
concern because most newly diagnosed persons have been
infected for several months to years, providing time for drug-
resistant viruses to decay to levels that conventional testing is
not able to detect.
Drug resistance mutations at frequencies detectable by
conventional genotyping are known to reduce the efﬁcacy of
ART; however, there is increasing interest in the clinical
consequences of these minority drug-resistant variants not
detected by conventional genotyping. Earlier observations
have suggested that persisting minority drug resistance in
persons previously exposed to non-nucleoside reverse tran-
scriptase inhibitors (NNRTIs) could lead to poor virologic
outcomes under a subsequent NNRTI-containing regimen
[17,18]. However, the clinical signiﬁcance of minority
mutations in drug-naı ¨ve persons is poorly understood.
We previously developed sensitive real-time PCR assays to
examine minority drug-resistant variants in HIV-1 clinical
samples [19]. These tests were validated on pre-ART wild-type
HIV samples from the early 1980s to establish cutoffs that are
above the mutation frequencies appearing with natural
quasispecies variation. At these cutoffs the PCR assays are
10- to 67-fold more sensitive than conventional genotyping.
The clinical application of this methodology is further
supported by the examination of HIV-1 from infected women
provided nevirapine to prevent mother-to-child HIV-1 trans-
mission. This testing did not detect nevirapine resistance in
antiretroviral drug–naı ¨ve women prior to receiving nevir-
apine and identiﬁed a greater emergence of resistance
mutations in these women after nevirapine exposure com-
pared to bulk sequencing [20].
Here we report two studies based on sensitive real-time
PCR. First, we performed a cross-sectional study to identify
transmitted resistance mutations at low levels (0.4%–19%) in
newly diagnosed individuals infected with subtype B HIV-1.
For this, we examined samples from individuals who, by
conventional genotyping, appeared to have wild-type infec-
tions and another group of persons who had at least one
resistance-associated mutation. Second, we performed a
retrospective case-control study on another group of partic-
ipants to assess the impact of baseline minority treatment-
relevant resistance mutations on the ability of ART to
suppress virus replication. These ﬁndings shed light on both
the prevalence of transmitted drug resistance and the clinical
consequences of minority drug resistance mutations in the
ART-naı ¨ve.
Materials and Methods
Study Populations
Cross-sectional analysis of transmitted drug resistance
mutations. The populations for the cross-sectional study
consisted of two groups of newly diagnosed HIV-1 subtype B-
infected ART-naı ¨ve individuals (Figure 1; Table 1). The ﬁrst
group included 205 persons from Los Angeles and Chicago
diagnosed with HIV-1 within 6 mo prior to enrollment into a
CDC behavioral characterization study and who were
determined to have wild-type infections by conventional
sequencing (wild-type group). The wild-type samples were
randomly selected to achieve the target sample size of greater
than 1.5 times the number of resistance samples in the parent
cohort. The parent cohort consisted of 586 individuals
examined in 2003–2005 who self-reported by questionnaire
their clinical history and ART-naı ¨ve status [21]. The overall
prevalence of drug resistance in the parent cohort was 20.7%
by conventional genotyping. The second cross-sectional study
group consisted of 303 individuals who had at least one drug
resistance mutation detected by conventional genotyping
(Figure 1; Table 1, mutant group). Because only a minor
proportion of transmitted HIV has bulk sequence–detectable
resistance mutations, we tested for hidden low-frequency
mutations in all available majority resistance samples. Of
these specimens, 119 were from the same Los Angeles–
Chicago parent cohort as the wild-type group, and 84 were
collected in 1997–2001 from ten major urban areas in the US
[1,21], representing nearly all (. 94%) of the resistance
samples in each parent cohort. The remaining 100 samples
were collected from individuals in Canada in 2000–2001 [3].
The ART-naı ¨ve status of individuals with sequence-detect-
able resistance was determined by personal interview and
medical chart review, if available, or physician reporting as
previously described [1,3]. All samples were collected as part
of HIV surveillance studies under institutional review board
approval (CDC IRB protocol nos. 1774, 3621, and 3910) and
were provided without personal identiﬁers. The patients
consented to storage of their blood samples for drug
resistance testing. More than half (52%) of all the US samples
were from MSM (men who have sex with men), heterosexual
exposure was reported for 34% of the population, and 14%
of the cohort were non-MSM participants who engaged in
intravenous drug use.
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Minority HIV-1 Resistance and TreatmentCase-control study evaluating the impact of minority drug
resistance. To evaluate whether minority variants with
resistance mutations inﬂuence the virologic response to
ART, we performed a retrospective case-control study using
real-time PCR to test baseline pre-treatment samples from
ART-naı ¨ve persons in the US who had participated in
treatment studies with efavirenz/lamivudine (EFV/3TC) plus
abacavir (ABC) or zidovudine (ZDV) (GlaxoSmithKline trials
CNA 30021 and CNA 30024) during 2000–2003 (Figure 2;
Table 1, case-control group) [22,23]. We analyzed blinded
plasma-virus samples, all wild-type by conventional genotyp-
ing, from participants who experienced virologic treatment
failure and a control group of participants who suppressed
virus replication during the 48-wk study period. Because we
expected very few cases with minority resistance using the
assay cutoffs we established, all 95 participants who failed
treatment and had wild-type baseline genotypes were
included. The total percentage of participants experiencing
virologic failure for the two GSK studies was 9% for CNA
30021 and 5% for CNA 30024 (Figure 2). Virologic failure was
deﬁned as (1) rebound of two consecutive plasma HIV-1 RNA
levels to . 50 copies/ml after achieving   50 copies/ml during
randomized treatment, or (2) plasma HIV-1 RNA levels never
achieving suppression of   50 copies/ml with or without the
discontinuation of treatment due to insufﬁcient viral load
response.
Although all cases of virologic failure were chosen for
evaluation, we analyzed only a subset the 964 total success
samples potentially introducing a sampling bias. To minimize
this bias, we made a conservative assumption that only 2% of
the samples would have minority resistance. Using this
expected proportion, a minimum sample size (n ¼ 209) was
determined (nQuery Advisor, Statistical Solutions) so that a
95% conﬁdence interval (CI) for minority resistance in the
treatment successes would not cover zero (95% CI 0.001–
0.039). Our ﬁnal sample size of 221 success samples exceeded
this minimum. The ﬁrst 70 success samples were simply the
ﬁrst enrolled who met the success criteria; the remaining 151
were selected randomly. The success samples tested repre-
sented 23% of all treatment successes from the two GSK
studies. Fifty-seven percent of the success samples tested were
from CNA 30021, and 43% were from CNA 30024, which was
similarly proportional to the contribution of participants
remaining at the completion of both studies (CNA 30021 n ¼
Figure 1. STROBE-Type Flow Diagram for the Retrospective Cross-Sectional (Newly Diagnosed Surveillance) Study Illustrating Drug Resistance in the
Parent Cohorts and the Sample Selection for Real-Time PCR Resistance Testing
Additional details are provided in Table 1.
doi:10.1371/journal.pmed.0050158.g001
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Minority HIV-1 Resistance and Treatment583, 54%; CNA 30024 n¼490, 46%). We tested these samples
for three treatment-relevant reverse transcriptase (RT)
mutations, K103N, Y181C, and M184V. Testing was per-
formed on archived specimens which, after review of
participants’ consent and sample masking, the CDC IRB
determined did not involve research on identiﬁable individ-
uals. All p-values for the (exact) Wilcoxon rank sum tests were
computed using StatXact version 6.2 (Cytel Software). The p-
value for the Fisher exact test and the logistic model for
treatment success/failure were obtained from SAS version 9.1
(SAS Institute).
Primary Virus Template Amplification
HIV-1 genomic RNA from the US samples was extracted
(Qiagen UltraSens RNA kit or Roche Amplicor) from 200 ll
of patient plasma or serum. The samples sent from the Public
Health Agency of Canada’s HIV/Retrovirology Laboratory
were provided as puriﬁed RNA. A region of the HIV-1
template that included nucleotide (nt) 1 of protease (PR) to nt
777 of RT was RT-PCR ampliﬁed as previously described [19].
This RT-PCR template was used in the real-time PCR testing
for drug resistance mutations.
Sensitive Real-Time PCR Drug Resistance Testing
The general principle of the real-time PCR testing for
subtype B clinical specimens has been described in detail [19].
Brieﬂy, the protocol compares the difference in the threshold
ampliﬁcation cycles (DCT) between mutation-speciﬁc reac-
tions and the total virus copy reaction for the sample. A
qualitative determination of whether the sample had detect-
able resistance mutations is based on previously validated
DCT cutoffs for each mutation. We have previously reported
that the real-time PCR assays are able to detect mutant
sequences at levels as low as 0.001%–0.2% when testing
prepared mixtures of cloned virus sequences [19]. However,
with the quasispecies diversity in clinical samples, we found it
was necessary to use more conservative cutoff values to gain
conﬁdence in our ability to speciﬁcally detect transmitted
drug resistance. Thus, for each mutation, we had established
assay cut-offs above the background reactivity observed when
testing wild-type virus samples from the early 1980s pre-
antiretroviral era (Table 2) [19].
All real-time PCRs were performed in duplicate, and mean
DCTs were used for interpreting the results. The reactions
were performed in a total volume of 50 ll/well in 96-well PCR
plates using iCycler real-time PCR thermocyclers with optical
units (Bio-Rad) and AmpliTaq Gold polymerase (2.5 U/
reaction; Applied Biosystems). Final reagent concentrations
were 320 nM for the forward and reverse primers, 160 nM
probe(s), and 400 mM dNTPs. Wild-type virus samples were
tested for eight mutations: L90M in PR; and M41L, K70R,
K103N, Y181C, M184V, and T215Y/F in RT. The 303 samples
in the mutant group were tested for minority mutations not
detected by conventional genotyping, which included 222 for
L90M, 101 for M41L, 251 for K70R, 202 for K103N, 200 for
Y181C, 260 for M184V, and 209 for 215Y/F mutations.
Cloning and Sequence Verification
To verify newly detected minority resistance mutations, a
709 bp PR-RT region (nt 8 of PR to nt 420 of RT) or a 651 bp
region of RT (nt 57–708 of RT) was ampliﬁed from the
primary RT-PCR of the specimen and cloned (pCR2.1 vector
with Top 10F’ E. coli, Invitrogen). Typically, 126 white colonies
(ranging from 84 to 168 in batches of 42 clones) were
screened as previously described [20], using the same real-
time PCR test that had identiﬁed the low-frequency mutant
in the sample. Colonies testing positive underwent double-
strand chain-termination sequencing (Big Dye kit v1.1,
Applied Biosystems).
Table 1. Characteristics and Conventional Drug Resistance Genotypes of Newly Diagnosed Drug-Naı ¨ve Populations Sampled for
Sensitive Real-Time PCR Drug Resistance Testing in the Cross-Sectional and Case-Control Studies
Category Group Cross-Sectional Studies Case-Control Study
Los Angeles and
Chicago (2003–
2005), n ¼ 586 [21]
Sentinel Surveillance
of Ten US Cities (1997–
2001), n ¼ 1,082 [1]
Primary Care Reported
to Public Health Canada
(2000–2001) [3]
GSK Trials CNA 30021
and CNA 30024 (2000–
2003), n ¼ 1,419 [22,23]
Gender Male 90% 81% 83% 81%
Female 10% 19% 17% 19%
Ethnicity White 32% 44% 76% 53%
Black/African 30% 31% 0
a 24%
Hispanic 30% 22% 2% 20%
Native/aboriginal 1% 0
a 17% 0
a
Asian/other 7% 3% 5% 31%
Infection duration
b 24% recent, 76% chronic 27% recent, 73% chronic 31% recent, 69% chronic NT
Drug resistance
prevalence (bulk)
20.7% 8.3% 8.1% 8.4%
c
Subset(s) analyzed
d Wild-type samples 205 (wild-type group)
e — — 316 (case-control group)
f
Mutant samples 119 (mutant group)
e 84 (mutant group)
e 100 (mutant group)
e —
aNone reported.
bRecency of infection was determined using the Vironostika HIV-1 LS EIA (bioMerieux), recent ¼ , 4–6 mo.
cBaseline drug resistance prevalence estimated from genotyping 21% of cohort.
dWild-type samples have no drug resistance mutations, and mutant samples have   1 major drug resistance mutation by conventional bulk sequencing.
eMinority resistance in these populations was assessed by testing with a panel of eight key resistance mutations.
fSamples were tested for the three most common resistance mutations relevant to the treatment regimens.
NT, not tested.
doi:10.1371/journal.pmed.0050158.t001
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Minority HIV-1 Resistance and TreatmentResults
Minority Drug Resistance Mutations in the Cross-Sectional
Wild-Type Virus Group
Table 3 describes the real-time PCR test results for the
205 drug-naı ¨ve individuals with wild-type genotypes by
conventional genotyping. The eight mutations tested were
detected at least once as a minority variant in 34 (17%)
samples (Figure 3). We found that the K70R thymidine analog
mutation (TAM) [24] was the most prevalent minority
mutation (10/205, 5%), followed by the M41L TAM, which
was found in nine samples (4.5%). One-half of the K70R
mutations (5/10) were in samples that also had M41L. The
remaining resistance mutation assays identiﬁed eight (4%)
K103N, seven (3.5%) L90M, three (1.5%) Y181C, two (1.5%)
M184V, one (0.5%) T215Y, and four (2%) T215F samples. Four
samples (2% overall) had the following mutations to two drug
classes: L90MþM184V, L90MþY181C, Y181CþT215F, and
L90MþM41LþK70R.
Minority Drug Resistance Mutations in the Cross-Sectional
Mutant Virus Group
Figure 3 and Table 4 show the real-time PCR test results for
the 303 specimens known to have at least one drug resistance
mutation by conventional genotyping. We identiﬁed minority
mutations in a total of 30 (10%) samples, which added 6/222
(3%) samples with L90M, 9/101 (9%) with M41L, 14/251 (6%)
with K70R, 2/202 (1%) with K103N, 8/200 (4%) with Y181C, 6/
260 (2%) with M184V, 10/209 (5%) with T215Y, and 13/209
(6%) with T215F. This again showed that all resistance
mutations are also present as minor variants. As was seen with
the wild-type virus group, the TAMs M41L and K70R were the
most common low-frequency mutations. Minority (between
1% and 19%) NNRTI resistance mutations were found only
in samples collected after 2002.
Multi-Drug-Class Resistance Mutations in Cross-Sectional
Analysis of Transmitted Viruses
We also examined whether the newly detected minority
mutations increased the prevalence of multi-drug class
Figure 2. STROBE-Type Flow Diagram for the Retrospective Case-Control Treatment Study Illustrating the Parent Cohort (Blue) Outcomes and Sample
Selection for Real-Time PCR Resistance Testing
doi:10.1371/journal.pmed.0050158.g002
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Minority HIV-1 Resistance and Treatmentresistance in the cross-sectional study. We found that some of
the newly identiﬁed minority mutations within the mutant
virus group samples were associated with resistance to drugs
from classes for which resistance was not detected by
conventional genotyping. Minority mutations to drugs in
other classes were identiﬁed in 21/303 (7%) mutant virus
samples. The majority of the class increases were in samples
that had mutations to only one drug class by conventional
genotyping, resulting in an increased prevalence of dual-class
mutations from 14% to 18% (a 27% increase). The prevalence
of resistance mutations to three drug classes doubled from the
2% detectable by conventional genotyping to 4%. Addition-
ally, in 11 (44%) of 25 samples that had both majority
nucleoside reverse transcriptase inhibitor (NRTI) mutations
and minority variants, resistance was expanded to impact
another drug within the NRTI class. Combining the minority
mutations detected in the wild-type and mutant virus groups
we found a cumulative increase in transmitted   2-class
resistance mutations from 20% to 27% (a 35% increase).
Minority Drug-Resistant Variant Confirmation by Clonal
Sequencing
Clonal sequencing conﬁrmed minority mutations in ten of
ten randomly selected positive samples from the wild-type and
mutant virus groups. For the three mutant virus samples
positive for M184V, clonal analysis found the mutation to be at
frequencies of 5.5%, 1.4%, and 0.6% (DCTs of 7.8, 7.5, and 8.4
cycles, respectively) (sequences submitted to GenBank [http://
www.ncbi.nlm.nih.gov/Genbank/index.html], accession num-
bers EU439613–EU439615). The bulk genotypes of these three
specimens revealed only one resistance-associated mutation
for each: K70R, K219Q, and K103S, respectively. The 184V
clones from the ﬁrst two samples showed linkage to TAMs.
Association of Minority Drug-Resistant Variants with
Virologic Failure in the Case-Control Group
Real-time PCR testing for three relevant mutations showed
that nine of the 316 baseline case-control samples had one or
two minority mutations (Figure 4; Table 5). Unmasking after
test completion revealed that seven (7.4%) of the minority
resistance samples were among the 95 participants who
experienced virologic failure, and two (0.9%) with minority
resistance were among the 221 treatment successes (p ¼
0.0038, two-sided Fisher exact test) (Table 6). Hence, seven
(78%) of the nine participants with minority resistance
mutations experienced virologic failure. One participant
who experienced failure within 2 mo had both the K103N
and the M184V mutations, which confer resistance to two
drugs in the regimen, EFV and 3TC, respectively. Four of ﬁve
available virologic failure bulk genotypes had majority levels
of the same resistance mutations we identiﬁed as being at
minority levels in their baseline samples. One participant
who had detectable Y181C at baseline experienced virologic
rebound with wild-type virus by week 12. Of the two
individuals who had resistance mutations at baseline and
maintained virus suppression during the 48-wk course of the
study, one person had K103N and the other Y181C; both had
been treated with the ABCþ3TCþEFV regimen.
Statistical Analysis of Clinical Markers and Outcome in the
Case-Control Group
We assessed the impact of baseline virus load (VL) and
CD4
þ T cell count (CD4 count) on virologic success and
Table 2. Real-Time PCR Resistance Mutation Assay Cutoffs and
Relative Sensitivities for Clinical Sample Testing Established
Using Drug-Resistant and Pre-ART Wild-Type Clinical Samples
[19]
Assay DCT Cutoff (# Cycles) Cutoff Mean % Mutant Equivalence
L90M 10.5 0.4
M41L 10.0 0.8
K70R 7.0 2.0
K103N 10.0 0.9
Y181C 10.0 1.0
M184V 8.5 0.5
T215Y
a 10.5 1.0
T215F
b 10.5 0.7
aAlso detects 215H, N, and D revertants.
bAlso detects 215L, I, and V revertants.
doi:10.1371/journal.pmed.0050158.t002
Table 3. Minority Drug Resistance Mutations Detected in the
Wild-Type Group Cross-Sectional HIV-1 Samples Collected in the
US between 2003 and 2005
Sample ID Minority Mutations Recent Infection
a
2 L90M, Y181C
b No
5 L90M No
6 L90M No
9 M41L No
14 M41L Yes
23 Y181C Yes
28 L90M No
29 L90M No
55 T215F No
56 M41L, K70R Yes
59 T215F No
74 M41L Ind
83 K70R No
85 K70R No
88 L90M, M184V
b Yes
89 Y181C, T215F
b No
90 M184V No
92 L90M, M41L, K70R
b No
98 M41L, K70R Yes
102 K70R Yes
104 K103N Yes
109 M41L, K70R Yes
110 K70R Yes
122 K103N Ind
130 K103N Yes
132 M41L, K70R Yes
134 T215Y Yes
150 K103N Yes
167 K103N No
173 K103N No
177 K70R No
178 M41L No
181 K103N No
196 K103N No
aBy Vironostika HIV-1 LS EIA and in-house avidity index (see Text S1).
bTwo drug-class mutations.
Ind, indeterminate (two incidence tests not concordant).
doi:10.1371/journal.pmed.0050158.t003
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Minority HIV-1 Resistance and Treatmentfailure with regard the presence or absence of minority
resistance. The 307 participants with no evidence of
resistance had a median CD4 count and VL of 240 cells/
mm
3 (range 50–650 cells/mm
3) and 10
5.07 copies/ml (range¼
10
3.08–10
5.90 copies/ml), respectively. These values are similar
to the median CD4 count of 230 cells/mm
3 (range 45–560
cells/mm
3) and VL of 10
4.95 copies/ml (range 10
3.70–10
5.52
copies/ml) for the nine participants with minority resistance
(CD4 count p ¼ 0.416, VL p ¼0.493, Wilcoxon rank sum test).
No signiﬁcant difference was found in VL (p ¼ 0.43) or CD4
count (p ¼ 0.316) between those with baseline minority
resistance who experienced failure and all treatment suc-
cesses (Wilcoxon rank sum test). However, overall, VL was
signiﬁcantly higher when all failures (cases) were grouped
(10
5.26 copies/ml) as compared to all successes (controls)
(10
4.95 copies/ml) (p , 0.0001); and, conversely, CD4 count was
signiﬁcantly lower in the treatment failure group (227 versus
254 cells/mm
3, p ¼ 0.023) (Wilcoxon rank sum test). The two
individuals with minority K103N and Y181C who successfully
suppressed virus had baseline VLs of 10
4.11 and 10
3.70 copies/
ml, respectively. These VLs are well below the medians but
within the ranges observed for both the failures and successes
with no resistance.
In a logistic model for the probability of treatment success,
with log10 VL and minority resistance as independent
variables, persons with low-frequency resistance mutations
at baseline had 11.2 times the odds of experiencing treatment
failure versus those in whom minority resistance was
undetectable (p¼0.004, 95% CI 2.2–58.8, coefﬁcient estimate
¼  2.414, standard error [SE] ¼ 0.839). For log10 VL as the
variable, the coefﬁcient estimate was  0.794 (p ¼ 0.0002, SE ¼
0.214). The coefﬁcient at intercept was 4.919 (p , 0.0001, SE¼
1.108). Although the number of people with low-frequency
resistance was small for both virologic failure and treatment
success, seven and two respectively, model diagnostics
supported the ﬁt of a logistic model to the data.
Discussion
Using assays validated for drug resistance mutations in
HIV-1 clinical samples, we identiﬁed, in ART-naı ¨ve persons
from the US and Canada, a substantial number of minority
mutant viruses at levels above the natural quasispecies
Figure 3. Real-Time PCR Mutation Test Results (DCT) for the Cross-Sectional Group
The samples positive for minority resistance are emphasized (DCT results above 13 cycles are not shown). The wild-type and mutant groups were tested
for eight key resistance mutations. Horizontal bar (—) denotes the assay cutoff for the mutation. Samples falling below this bar are positive for the
mutation. The clonal frequencies are shown for encircled data points.
doi:10.1371/journal.pmed.0050158.g003
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Minority HIV-1 Resistance and Treatmentfrequency of each mutation. The preponderance of minority
resistance mutations implies that a considerable proportion
of transmitted drug resistance decayed to low levels by the
time of HIV-1 diagnosis. The detection of minority resistance
mutations in 17% of the wild-type virus group, part of a US
cohort of newly diagnosed HIV-1–infected persons that had
20% bulk sequence-detectable primary drug resistance,
suggests that bulk sequencing missed 40% of the resistance
samples in this population. The frequent occurrence of drug
resistance likely reﬂects a high prevalence of ART in these
locations and suggests that transmission of HIV-1 from
antiretroviral drug-experienced persons expressing virus is
not uncommon.
Minority HIV-1 variants increased the observed frequency
of transmitted multi-drug resistance genotypes in the cross-
sectional study group by one-third, emphasizing that drug-
naı ¨ve individuals may harbor hidden resistance to drugs from
different classes. The several cases of low-frequency drug
resistance mutations that we identiﬁed is likely an under-
estimation of minority resistance prevalence, because only
eight of the nearly 40 codons in PR and RT that are associated
with drug resistance were evaluated [25]. Clonal sequencing
and resistance mutation linkage analysis (see Figure S1 and
Text S2) have shown that multiple minority drug resistance
mutations can be present and that these mutations may
coexist unlinked from majority mutations in ART-naı ¨ve
persons.
The presence of unlinked mutations in multidrug-resistant
ART-naı ¨ve persons might reﬂect mutations that were once
linked in oligoclonal populations and then independently
reverted as a result of mutation (ﬁtness) modulations or
immune selection [15,26,27]. Alternatively, some dissociated
mutations could have been a result of infections with more
than one drug-resistant variant, possibly through needle
sharing or, less frequently, by sexually acquired super-
infection [28]. Of note, we found that in the wild-type virus
group minority mutations were equally prevalent in recently
infected persons and in those infected for longer duration
(17% of both groups). This might suggest that a considerable
proportion of transmitted drug resistance decays very
rapidly. A better understanding of drug resistance trans-
mission and mutation decay requires sensitive testing of
longitudinal samples from a large number of acutely infected
persons with dissimilar drug resistance mutation genotypes.
With the knowledge that minority drug resistance can be
considerable in ART-naı ¨ve populations, we then assessed the
impact of low-frequency resistance mutations on treatment
responses in a case-control study of persons with no treat-
ment-relevant mutations detected by conventional genotyp-
ing. In the baseline samples of this previously ART-naı ¨ve
group we were again able to identify minority treatment-
relevant mutations. The minority mutations were signiﬁ-
cantly associated with virologic failure using the Fisher exact
test (p¼0.0038) and in a logistic model. These results suggest
that minority transmitted resistance mutations can be
clinically important.
We observed in the case-control study what appeared to be
a stronger association with treatment failure for participants
with minority resistance than that seen for resistance-
associated mutations detected by bulk genotyping [22,23]. A
virologic explanation for these seemingly disparate outcomes
is currently not evident, and the ﬁnding could be biased by
only a few samples having any of the three relevant resistance
mutations. Notably, a similar observation was recently made
with low-level RT-simian–human immunodeﬁciency virus
(SHIV) mutants in a macaque infection model. In that study,
minority NNRTI mutations were associated with virologic
failure, whereas viruses with resistance mutations at higher
Figure 4. Real-Time PCR Mutation Test Results (DCT) for Three
Treatment-Relevant Mutations in the Case-Control Study Group
Horizontal bar (—) denotes the assay cutoff for the mutation. Samples
falling below this bar are positive for the mutation.
doi:10.1371/journal.pmed.0050158.g004
Table 4. Minority Resistance Mutation Prevalence in 303 Mutant Virus Group Samples in the Cross-Sectional Study of Individuals from
the US (1997–2005) and Canada (2000–2001), and the Observed Increase in Prevalence for Each Mutation when Minority Variants Are
Included
Mutation Tested (Minority Prevalence) Change in Mutation Prevalence
a Percentage Change in Mutation Prevalence
b
L90M (3%) 8% ! 11% þ25%
M41L (10%) 9% ! 17% þ70%
K70R (6%) 9% ! 14% þ60%
K103N (1%) 19% ! 20% þ5%
Y181C (4%) 3% ! 6% þ100%
M184V (2%) 8% ! 10% þ23%
T215Y (3%) 17% ! 20% þ20%
T215F (5%) 2% ! 7% þ340%
aConventional mutation prevalence ! new mutation prevalence with minority variants added (rounded to nearest percent).
bReflects change in observed (nonrounded) mutation prevalence; 30 /303 (10%) of the mutant group samples had evidence of minority drug resistance mutations.
doi:10.1371/journal.pmed.0050158.t004
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Minority HIV-1 Resistance and Treatmentlevels detectable by sequencing were successfully suppressed
by the NNRTI regimen [29]. It is possible that some minor
variants have higher phenotypic resistance than the domi-
nant mutants, presumably due to additional mutations. These
minor variants could be less ﬁt than majority mutants in the
absence of drug, but more ﬁt under drug pressure, leading to
virologic failure. Additional studies are required to examine
these possibilities.
While we report a signiﬁcant association between poor
virologic suppression and minority levels of three mutations
relevant to two EFV-based regimens, the impact of a
particular minority resistance mutation on other drug
regimens is not entirely understood. Further investigation
with sensitive tests will help deﬁne the clinical signiﬁcance of
individual mutations in the context of speciﬁc drug (or drug
class) combinations. Data from those studies could assist with
the selection of regimens that are most active for persons
infected with drug-resistant viruses.
A limitation of our study is that, as with all self-reported
histories, some participants with resistance mutations may not
have disclosed previous exposure to antiretroviral drugs and,
therefore, did not represent cases of primary drug resistance.
Additionally, the small number of participants with detectable
minority resistance mutations in the case-control study may
have allowed for an artifactual association with virologic
failure. It may be possible that the higher median viral load in
the virologic failures versus the treatment successes allowed
for increased opportunities to detect minority mutations in
failures; however, this was not evident from the viral loads for
the failures with resistance, which were comparable to the
successes. A possible explanation for the low number of
detectable minority variants is that NNRTI resistance muta-
tions were not as prevalent during the period of the GSK
studies as they are today, as seen in the populations sampled
for our cross-sectional analysis. Additionally, the participants
in the case-control study may have had infections of
comparatively longer duration with substantially greater
decay of resistance to undetectable levels. Nevertheless, our
ﬁndings are in agreement with three other studies that
reported a signiﬁcant association between treatment failure
and minority NNRTI resistance mutations [18,30,31].
The prevalence of primary drug resistance in geographic
areas where ART is common suggests that initial therapies
can be signiﬁcantly impacted; therefore, efforts to prevent
transmission from ART-experienced persons are of great
importance. The association between minority resistance and
poor virologic suppression suggests a need for practical and
sensitive testing to identify drug-resistant variants before
treatment.
In conclusion, the data from drug-naı ¨ve persons demon-
strate that sensitive testing improves detection of HIV-1 drug
resistance mutations and, therefore, could be valuable not
only to HIV-1 surveillance but also to ART management,
particularly when treatment history is unavailable.
Supporting Information
Figure S1. Evidence of Minority Drug Resistance Mutation Linkage
and Dissociation by Mutation-Speciﬁc Amplicon Sequencing
A transmitted mutant group virus sample that had only K103N by
bulk genotyping also had an unlinked minority M184VþT215N
variant that was detected by the 215 PCR test. ‘‘...’’, nucleotides
from the contiguous sequence not shown.
Found at doi:10.1371/journal.pmed.0050158.sg001 (77 KB PDF).
Text S1. Protocol: Avidity Index Testing
Found at doi:10.1371/journal.pmed.0050158.sd001 (24 KB DOC).
Text S2. Supplemental Mutation Linkage Data
Found at doi:10.1371/journal.pmed.0050158.sd002 (34 KB DOC).
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Table 6. Fraction of Treatment Success or Failure Versus the
Presence of Detectable Minority Drug Resistance Mutations for
the 316 Treatment Study Participants Evaluated (Fisher exact
test, p ¼ 0.0038)
Mutation Status Treatment Success
(n ¼ 221)
Treatment Failure
(n ¼ 95)
No detectable drug
resistance mutation
219 (99.1%) 88 (92.6%)
Minority drug
resistance mutation
2 (0.9%) 7 (7.4%)
doi:10.1371/journal.pmed.0050158.t006
Table 5. Baseline Samples with Detectable Minority Mutations and Treatment Outcomes for Persons Who Participated in the NNRTI-
Based Treatment Studies (Case-Control Group)
Sample ID Baseline Minority Mutations Regimen Outcome Treatment Week Bulk Genotype Mutations at Failure
11 M184V ABCþ3TCþEFV Failure 48 Unk
25 M184V ABCþ3TCþEFV Failure 12 M184V
31 K103N ABCþ3TCþEFV Failure 8 K103N, M184V
41 K103N, M184V ABCþ3TCþEFV Failure 8 K103N, M184V
44 K103N ZDVþ3TCþEFV Failure 24 K103N
63 K103N ZDVþ3TCþEFV Failure 48 Unk
67 Y181C ABCþ3TCþEFV Failure 12 WT
193 Y181C ABCþ3TCþEFV Success — NA
251 K103N ABCþ3TCþEFV Success — NA
Unk, genotype not known; WT, wild-type virus; NA, not applicable; ZDV, zidovudine.
doi:10.1371/journal.pmed.0050158.t005
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Background Since the mid-1990s, several powerful antiretroviral drug
combinations have been developed that have greatly improved the
prognosis of HIV infection. All antiretroviral therapy (ART) regimens
combine drugs that act against HIV in different ways (so-called different
drug classes). Multiple drugs are necessary because HIV continually
accumulates random changes (mutations) in its genetic material
(genome). Some of these mutations make HIV resistant to individual
antiretroviral drugs, so a mixture of drugs is needed to keep the virus in
check. However, the efficacy of ART (which itself selects for drug-resistant
variants by giving them a growth advantage over drug-sensitive variants)
is substantially reduced when these variants account for more than
about 20% of the viruses in an infected person. This level of variant virus
can be detected in blood samples with a technique called bulk
sequencing. In North America and Europe, where ART has been widely
used for many years, around 20% of HIV-infected people who have taken
ART themselves develop this level of drug-resistant virus, which can be
transmitted by the same routes as nonresistant HIV (typically unpro-
tected sexual intercourse or needle sharing). In such cases, the person
acquiring drug-resistant HIV may experience treatment failure when
drugs later fail to work against the resistant virus. In these countries,
therefore, resistance testing by bulk sequencing is done routinely before
ART is initiated to decide which antiviral drugs are likely to be effective.
Why Was This Study Done? Several years usually elapse between the
time a person becomes infected with HIV and the time he or she starts
ART. During this time, the absence of selection pressure from antiviral
drugs means that transmitted drug-resistant variants tend to decline to
levels undetectable by bulk sequencing. These ‘‘minority drug-resistant
variants’’ can be detected using other more sensitive tests but it is not
known what proportion of HIV-infected people who have never taken
ART carry minority drug-resistant variants (the ‘‘prevalence’’ of these
variants). It is also unknown whether the presence of minority drug-
resistant variants reduces the success of ART. In this paper, the
researchers first report a ‘‘cross-sectional’’ study in North America using
a sensitive assay to determine the prevalence of minority drug-resistant
viruses among HIV-infected people who had never received ART. They
then investigate whether minority drug-resistant variants have any
impact on the effectiveness of ART in a ‘‘case-control’’ study.
What Did the Researchers Do and Find? In their cross-sectional study,
the researchers used a highly sensitive test for detecting mutations
(called a real-time PCR-based assay) to look for low levels of viruses
carrying any of eight major drug-resistance mutations in people with
newly diagnosed HIV infection who reported no prior treatment with
ART. Seventeen percent of the people who had only wild-type
(nonmutated) virus by bulk sequencing (205 participants) were found,
in fact, to carry low levels of virus variants with 1–3 drug-resistance
mutations; 2% of them carried viruses resistant to two different drug
classes (called multi-drug resistance). Among the people with resistance
mutations detected by bulk sequencing (303 participants), 10% had at
least one additional minority drug-resistant variant, often a viral variant
that was resistant to a drug class different from that detected by bulk
sequencing. In the case-control study, the researchers used their
sensitive assays to measure the levels of viruses containing any of the
three most common drug resistance mutations likely to affect viral
responses to the antiretroviral drugs efavirenz and lamivudine in 316
people just before they started their first HIV treatment, which included
these drugs. Of people for whom ART failed, 7% were infected with
minority drug-resistant virus variants at baseline compared with only
0.9% of people for whom ART worked; this difference was statistically
significant.
What Do These Findings Mean? The findings of the cross-sectional
study indicate that conventional bulk sequencing fails to detect a large
proportion of transmitted HIV drug resistance and suggest that the
transmission of drug-resistant variants from infectious ART-experienced
people to ART-naı ¨ve individuals might not be uncommon. The findings
of the case-control study suggest that the minority drug-resistant HIV
variants may have clinical consequences. That is, the presence of such
variants in individuals who have not previously taken ART may reduce
the efficacy of some ART regimens. However, the number of participants
meeting the criteria for analysis in the cross-sectional study was limited,
and the association between minority resistance and treatment failure
may have been influenced by other factors. Taken together, these
findings suggest that, to ensure that first-line ART is as effective as
possible, greater efforts should be made to prevent HIV transmission,
whether from ART-experienced or ART-naive people. However, because
data on minority drug-resistant virus are limited, more studies—
particularly with recent populations—are needed before testing for
these variants can be considered appropriate in the clinical management
of newly diagnosed HIV infection.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0050158.
  This study is further discussed in a PLoS Medicine Perspective by
Steven G. Deeks
  Information is available from the US National Institute of Allergy and
Infectious Diseases on HIV infection and AIDS
  HIV InSite has comprehensive information on all aspects of HIV/AIDS,
including links to fact sheets (in English, French, and Spanish) about
antiretrovirals and information on genetic testing for HIV drug
resistance
  NAM, a UK registered charity, provides information about all aspects of
HIVand AIDS, including fact sheets on types of HIV drug, drug
resistance, and resistance tests (in English, Spanish, French, Portu-
guese, and Russian)
  The US Centers for Disease Control and Prevention provides
information on HIV/AIDS and on treatment (in English and Spanish)
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